🔎 Trials Near Me

Hjem › Akut myelogen leukemi › New York › Buffalo

Kliniske studier for Akut myelogen leukemi i Buffalo, NY

19 studier for Akut myelogen leukemi søker deltakere på steder i og rundt Buffalo (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Roswell Park Cancer Institute, Buffalo
Alder 60 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT07437950

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RekruttererFase 2
  • Roswell Park Cancer Institute, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 5. okt. 2026 · NCT05564390

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

RekruttererFase 3
  • Roswell Park Comprehensive Cancer Center, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 25. sep. 2026 · NCT06852222

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

RekruttererFase 1
  • Roswell Park Cancer Institute, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2026 · NCT06871410

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Roswell Park Cancer Institute, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Roswell Park Cancer Institute, Buffalo
Alder 18 til 59 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RekruttererFase 2
  • Roswell Park Cancer Institute, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RekruttererFase 3
  • Roswell Park Cancer Institute, Buffalo
6 Months – 21 Years · Alle kjønn · Oppdatert 17. sep. 2026 · NCT04293562

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

RekruttererFase 1/2
  • Roswell Park Comprehensive Cancer Center, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 11. sep. 2026 · NCT06969430

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RekruttererFase 3
  • State University of New York at Buffalo, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

RekruttererFase 1
  • Roswell Park Comprehensive Cancer Center, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 20. aug. 2026 · NCT06001788

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

RekruttererFase 2
  • Roswell Park Cancer Institute, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 10. jul. 2026 · NCT05442216

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

RekruttererObservasjonsstudie
  • Roswell Park Cancer Institute, Buffalo
Alle aldre · Alle kjønn · Oppdatert 6. jul. 2026 · NCT01351545

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

RekruttererFase 2/3
  • Roswell Park Comprehensive Cancer Center, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 30. apr. 2026 · NCT04256317

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

RekruttererFase 1/2
  • Roswell Park Comprehensive Cancer Center, Buffalo
Alder 12 og eldre · Alle kjønn · Oppdatert 24. mar. 2026 · NCT04988555

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RekruttererFase 1
  • Roswell Park Comprehensive Cancer Center, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 13. mar. 2026 · NCT05735184

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

RekruttererFase 1
  • Roswell Park Cancer Institute, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 16. jan. 2026 · NCT05143996

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

RekruttererFase 1
  • Roswell Park Cancer Institute, Buffalo
Alder 18 og eldre · Alle kjønn · Oppdatert 24. sep. 2025 · NCT06501196

Akut myelogen leukemi-studier i andre byer

Andre studier i Buffalo

Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.